Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

KRSNAA DIAGNOSTICS vs DR. LAL PATHLABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    KRSNAA DIAGNOSTICS DR. LAL PATHLABS KRSNAA DIAGNOSTICS/
DR. LAL PATHLABS
 
P/E (TTM) x - 73.8 - View Chart
P/BV x 1.9 24.6 7.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 KRSNAA DIAGNOSTICS   DR. LAL PATHLABS
EQUITY SHARE DATA
    KRSNAA DIAGNOSTICS
Mar-21
DR. LAL PATHLABS
Mar-21
KRSNAA DIAGNOSTICS/
DR. LAL PATHLABS
5-Yr Chart
Click to enlarge
High RsNA2,735 0.0%   
Low RsNA1,305 0.0%   
Sales per share (Unadj.) Rs998.8189.7 526.4%  
Earnings per share (Unadj.) Rs284.535.6 799.7%  
Cash flow per share (Unadj.) Rs342.144.8 763.0%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Avg Dividend yield %NM1.0- 
Book value per share (Unadj.) Rs355.5144.6 245.8%  
Shares outstanding (eoy) m6.5083.34 7.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x010.6 0.0%   
Avg P/E ratio x056.8 0.0%  
P/CF ratio (eoy) x045.1 0.0%  
Price / Book Value ratio x014.0 0.0%  
Dividend payout %056.2 0.0%   
Avg Mkt Cap Rs m0168,365 0.0%   
No. of employees `000NANA-   
Total wages/salary Rs m2962,737 10.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m6,49215,813 41.1%  
Other income Rs m122513 23.8%   
Total revenues Rs m6,61516,326 40.5%   
Gross profit Rs m3,4664,363 79.4%  
Depreciation Rs m374772 48.5%   
Interest Rs m259160 162.1%   
Profit before tax Rs m2,9553,944 74.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105979 112.9%   
Profit after tax Rs m1,8492,965 62.4%  
Gross profit margin %53.427.6 193.5%  
Effective tax rate %37.424.8 150.7%   
Net profit margin %28.518.7 151.9%  
BALANCE SHEET DATA
Current assets Rs m2,48111,452 21.7%   
Current liabilities Rs m1,8382,743 67.0%   
Net working cap to sales %9.955.1 18.0%  
Current ratio x1.44.2 32.3%  
Inventory Days Days2521 118.8%  
Debtors Days Days4115 264.6%  
Net fixed assets Rs m3,5644,881 73.0%   
Share capital Rs m2,489833 298.6%   
"Free" reserves Rs m-17811,219 -1.6%   
Net worth Rs m2,31012,053 19.2%   
Long term debt Rs m1,6801 141,137.8%   
Total assets Rs m6,04516,333 37.0%  
Interest coverage x12.425.6 48.3%   
Debt to equity ratio x0.70 736,253.2%  
Sales to assets ratio x1.11.0 110.9%   
Return on assets %34.919.1 182.3%  
Return on equity %80.024.6 325.4%  
Return on capital %80.534.0 236.6%  
Exports to sales %00-   
Imports to sales %00.7 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA105 0.0%   
Fx inflow Rs m0143 0.0%   
Fx outflow Rs m0105 0.0%   
Net fx Rs m038 0.0%   
CASH FLOW
From Operations Rs m1,0263,982 25.8%  
From Investments Rs m-611-2,120 28.8%  
From Financial Activity Rs m308-1,386 -22.3%  
Net Cashflow Rs m723476 151.9%  

Share Holding

Indian Promoters % 27.4 55.2 49.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 36.2 32.6 111.1%  
FIIs % 6.0 26.8 22.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 72.6 44.8 162.2%  
Shareholders   75,554 125,953 60.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare KRSNAA DIAGNOSTICS With:   THYROCARE TECHNOLOGIES  SHALBY   MAX HEALTHCARE INSTITUTE  ASPIRA PATHLAB & DIAGNOSTICS   KMC SPECIALITY HOSPITALS  



Today's Market

Sensex Up 400 Points, Nifty Above 18,250; Tech Mahindra & Tata Motors Surge 5%(10:30 am)

Asian share markets are trading higher today, boosted by gains in US shares that hit record highs as Tesla topped US$1 tn in value.

Related Views on News

DR. LAL PATHLABS 2020-21 Annual Report Analysis (Annual Result Update)

Aug 12, 2021 | Updated on Aug 12, 2021

Here's an analysis of the annual report of DR. LAL PATHLABS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DR. LAL PATHLABS. Also includes updates on the valuation of DR. LAL PATHLABS.

DR. LAL PATHLABS Announces Quarterly Results (1QFY22); Net Profit Up 370.8% (Quarterly Result Update)

Aug 3, 2021 | Updated on Aug 3, 2021

For the quarter ended June 2021, DR. LAL PATHLABS has posted a net profit of Rs 1 bn (up 370.8% YoY). Sales on the other hand came in at Rs 6 bn (up 128.0% YoY). Read on for a complete analysis of DR. LAL PATHLABS's quarterly results.

More Views on News

Most Popular

5 Green Energy Stocks to Watch as India Readies for a Revolution(Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You...(Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy?(Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally(Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

India's Big PSU Selloff: Watch Out for these Top Stocks(Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

KRSNAA DIAGNOSTICS SHARE PRICE


Oct 26, 2021 03:06 PM

TRACK KRSNAA DIAGNOSTICS

  • Track your investment in KRSNAA DIAGNOSTICS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON KRSNAA DIAGNOSTICS

KRSNAA DIAGNOSTICS 5-YR ANALYSIS

COMPARE KRSNAA DIAGNOSTICS WITH

MARKET STATS